These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 20812900)

  • 1. Updates of mTOR inhibitors.
    Zhou H; Luo Y; Huang S
    Anticancer Agents Med Chem; 2010 Sep; 10(7):571-81. PubMed ID: 20812900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the mTOR kinase domain: the second generation of mTOR inhibitors.
    Zhang YJ; Duan Y; Zheng XF
    Drug Discov Today; 2011 Apr; 16(7-8):325-31. PubMed ID: 21333749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment.
    Lv X; Ma X; Hu Y
    Expert Opin Drug Discov; 2013 Aug; 8(8):991-1012. PubMed ID: 23668243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy.
    Wander SA; Hennessy BT; Slingerland JM
    J Clin Invest; 2011 Apr; 121(4):1231-41. PubMed ID: 21490404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.
    Feldman ME; Apsel B; Uotila A; Loewith R; Knight ZA; Ruggero D; Shokat KM
    PLoS Biol; 2009 Feb; 7(2):e38. PubMed ID: 19209957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dissecting the role of mTOR: lessons from mTOR inhibitors.
    Dowling RJ; Topisirovic I; Fonseca BD; Sonenberg N
    Biochim Biophys Acta; 2010 Mar; 1804(3):433-9. PubMed ID: 20005306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mTOR pathway inhibitors in cancer therapy: moving past rapamycin.
    Wacheck V
    Pharmacogenomics; 2010 Sep; 11(9):1189-91. PubMed ID: 20860456
    [No Abstract]   [Full Text] [Related]  

  • 8. Current and future directions in mammalian target of rapamycin inhibitors development.
    Fasolo A; Sessa C
    Expert Opin Investig Drugs; 2011 Mar; 20(3):381-94. PubMed ID: 21299441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting mTOR signaling pathway in ovarian cancer.
    Mabuchi S; Hisamatsu T; Kimura T
    Curr Med Chem; 2011; 18(19):2960-8. PubMed ID: 21651485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
    Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
    Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mTOR kinase inhibitors as potential cancer therapeutic drugs.
    Sun SY
    Cancer Lett; 2013 Oct; 340(1):1-8. PubMed ID: 23792225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current development of the second generation of mTOR inhibitors as anticancer agents.
    Zhou HY; Huang SL
    Chin J Cancer; 2012 Jan; 31(1):8-18. PubMed ID: 22059905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
    Grzybowska-Izydorczyk O; Smolewski P
    Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs).
    Feldman ME; Shokat KM
    Curr Top Microbiol Immunol; 2010; 347():241-62. PubMed ID: 20549474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.
    Yu K; Toral-Barza L; Shi C; Zhang WG; Lucas J; Shor B; Kim J; Verheijen J; Curran K; Malwitz DJ; Cole DC; Ellingboe J; Ayral-Kaloustian S; Mansour TS; Gibbons JJ; Abraham RT; Nowak P; Zask A
    Cancer Res; 2009 Aug; 69(15):6232-40. PubMed ID: 19584280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway.
    Smolewski P
    Anticancer Drugs; 2006 Jun; 17(5):487-94. PubMed ID: 16702804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin.
    Zou Z; Chen J; Yang J; Bai X
    Curr Cancer Drug Targets; 2016; 16(4):288-304. PubMed ID: 26563881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR.
    Chen SM; Liu JL; Wang X; Liang C; Ding J; Meng LH
    Biochem Pharmacol; 2012 May; 83(9):1183-94. PubMed ID: 22305748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATP-competitive inhibitors of mTOR: an update.
    Schenone S; Brullo C; Musumeci F; Radi M; Botta M
    Curr Med Chem; 2011; 18(20):2995-3014. PubMed ID: 21651476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting mTOR and Metabolism in Cancer: Lessons and Innovations.
    Magaway C; Kim E; Jacinto E
    Cells; 2019 Dec; 8(12):. PubMed ID: 31817676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.